Literature DB >> 29050825

Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy.

Paul T McIntosh1, Lisa D Hobson-Webb2, Zoheb B Kazi1, Sean N Prater1, Suhrad G Banugaria1, Stephanie Austin1, Raymond Wang3, David S Enterline4, Donald P Frush5, Priya S Kishnani6.   

Abstract

BACKGROUND: Recombinant human acid α-glucosidase (rhGAA) enzyme replacement therapy (ERT) has prolonged survival in infantile Pompe disease (IPD), but has unmasked central nervous system (CNS) changes.
METHODS: Brain imaging, consisting of computed tomography (CT) and/or magnetic resonance imaging (MRI), was performed on 23 patients with IPD (17 CRIM-positive, 6 CRIM-negative) aged 2-38months. Most patients had baseline neuroimaging performed prior to the initiation of ERT. Follow-up neuroimaging was performed in eight.
RESULTS: Sixteen patients (70%) had neuroimaging abnormalities consisting of ventricular enlargement (VE) and/or extra-axial cerebrospinal fluid accumulation (EACSF) at baseline, with delayed myelination in two. Follow-up neuroimaging (n=8) after 6-153months showed marked improvement, with normalization of VE and EACSF in seven patients. Two of three patients imaged after age 10years demonstrated white matter changes, with one noted to have a basilar artery aneurysm.
CONCLUSIONS: Mild abnormalities on brain imaging in untreated or newly treated patients with IPD tend to resolve with time, in conjunction with ERT. However, white matter changes are emerging as seen in Patients 1 and 3 which included abnormal periventricular white matter changes with subtle signal abnormalities in the basal ganglia and minimal, symmetric signal abnormalities involving the deep frontoparietal cerebral white matter, respectively. The role of neuroimaging as part of the clinical evaluation of IPD needs to be considered to assess for white matter changes and cerebral aneurysms.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acid maltase deficiency; Alglucosidase alfa; Blood-brain barrier; CT; Central nervous system; Enzyme replacement therapy; Glycogen storage disease type II; MRI; Neuroimaging; Neuromuscular diseases; Pompe disease; rhGAA

Mesh:

Substances:

Year:  2017        PMID: 29050825      PMCID: PMC5808895          DOI: 10.1016/j.ymgme.2017.10.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  31 in total

1.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.

Authors:  Priya S Kishnani; Wuh-Liang Hwu; Hanna Mandel; Marc Nicolino; Florence Yong; Deyanira Corzo
Journal:  J Pediatr       Date:  2006-05       Impact factor: 4.406

2.  Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.

Authors:  B J Ebbink; F K Aarsen; C M van Gelder; J M P van den Hout; N Weisglas-Kuperus; J Jaeken; M H Lequin; W F M Arts; A T van der Ploeg
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

Review 3.  Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis.

Authors:  E N Benveniste
Journal:  J Mol Med (Berl)       Date:  1997-03       Impact factor: 4.599

4.  Early cognitive development in children with infantile Pompe disease.

Authors:  Gail A Spiridigliozzi; James H Heller; Laura E Case; Harrison N Jones; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-10-28       Impact factor: 4.797

5.  Glycogenosis type II (Pompe). The fourth autopsy case in Japan.

Authors:  I Sakurai; A Tosaka; Y Mori; S Imura; K Aoki
Journal:  Acta Pathol Jpn       Date:  1974-11

6.  Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Shinn-Forng Peng; Wuh-Liang Hwu
Journal:  Pediatr Res       Date:  2006-07-20       Impact factor: 3.756

Review 7.  Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia.

Authors:  Y Persidsky; J Zheng; D Miller; H E Gendelman
Journal:  J Leukoc Biol       Date:  2000-09       Impact factor: 4.962

8.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

Authors:  P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith
Journal:  Neurology       Date:  2006-12-06       Impact factor: 9.910

9.  Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Chun-An Chen; Fuu-Jen Tsai; Wen-Hui Tsai; Jeng-Yi Shieh; Hsiang-Ju Huang; Wei-Chung Hsu; Tzu-Hsun Tsai; Wuh-Liang Hwu
Journal:  J Pediatr       Date:  2014-11-04       Impact factor: 4.406

10.  Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.

Authors:  Richard J Ing; D Ryan Cook; Resai A Bengur; Eric A Williams; John Eck; Guy de L Dear; Allison K Ross; Frank H Kern; Priya S Kishnani
Journal:  Paediatr Anaesth       Date:  2004-06       Impact factor: 2.556

View more
  19 in total

Review 1.  Gene therapy for glycogen storage diseases.

Authors:  Priya S Kishnani; Baodong Sun; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 2.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

3.  Therapeutic Benefit of Autophagy Modulation in Pompe Disease.

Authors:  Jeong-A Lim; Baodong Sun; Rosa Puertollano; Nina Raben
Journal:  Mol Ther       Date:  2018-05-03       Impact factor: 11.454

4.  Improved efficacy of a next-generation ERT in murine Pompe disease.

Authors:  Su Xu; Yi Lun; Michelle Frascella; Anadina Garcia; Rebecca Soska; Anju Nair; Abdul S Ponery; Adriane Schilling; Jessie Feng; Steven Tuske; Maria Cecilia Della Valle; José A Martina; Evelyn Ralston; Russell Gotschall; Kenneth J Valenzano; Rosa Puertollano; Hung V Do; Nina Raben; Richie Khanna
Journal:  JCI Insight       Date:  2019-03-07

Review 5.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

6.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

Authors:  Manuela Corti; Cristina Liberati; Barbara K Smith; Lee Ann Lawson; Ibrahim S Tuna; Thomas J Conlon; Kirsten E Coleman; Saleem Islam; Roland W Herzog; David D Fuller; Shelley W Collins; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2017-12       Impact factor: 5.032

7.  Novel approaches to quantify CNS involvement in children with Pompe disease.

Authors:  Aditi Korlimarla; Gail A Spiridigliozzi; Kelly Crisp; Mrudu Herbert; Steven Chen; Michael Malinzak; Mihaela Stefanescu; Stephanie L Austin; Heidi Cope; Kanecia Zimmerman; Harrison Jones; James M Provenzale; Priya S Kishnani
Journal:  Neurology       Date:  2020-06-09       Impact factor: 9.910

8.  Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.

Authors:  Jousef Alandy-Dy; Marie Wencel; Kathy Hall; Julie Simon; Yanjun Chen; Erik Valenti; Jade Yang; Deeksha Bali; Anita Lakatos; Namita Goyal; Tahseen Mozaffar; Virginia Kimonis
Journal:  Ann Transl Med       Date:  2019-07

9.  Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.

Authors:  Rossella Parini; Paola De Lorenzo; Andrea Dardis; Alberto Burlina; Alessandra Cassio; Paolo Cavarzere; Daniela Concolino; Roberto Della Casa; Federica Deodato; Maria Alice Donati; Agata Fiumara; Serena Gasperini; Francesca Menni; Veronica Pagliardini; Michele Sacchini; Marco Spada; Roberta Taurisano; Maria Grazia Valsecchi; Maja Di Rocco; Bruno Bembi
Journal:  Orphanet J Rare Dis       Date:  2018-02-08       Impact factor: 4.123

Review 10.  The Respiratory Phenotype of Pompe Disease Mouse Models.

Authors:  Anna F Fusco; Angela L McCall; Justin S Dhindsa; Lucy Zheng; Aidan Bailey; Amanda F Kahn; Mai K ElMallah
Journal:  Int J Mol Sci       Date:  2020-03-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.